Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a ...

Kuykendall has been in his current role since July 2022. Interesting fact: He has worked with Novo Nordisk for more than 18 ...

Novo Nordisk faces scrutiny over UK pharmacy sponsorships tied to weight-loss drugs, with critics citing conflicts of interest and regulatory breaches.

Weight-loss drug stocks were catapulted into the spotlight in 2024, creating a lucrative, groundbreaking, and high-stakes ...

As previously reported, Bernstein upgraded Novo Nordisk (NVO) to Market Perform from Underperform with a price target of DKK 600, up from DKK ...

Novo Nordisk petitions the FDA to exclude liraglutide from the 503B Bulks List, citing safety risks, lack of clinical need, ...

Pharmaceutical stalwart Novo Nordisk (NVO) can’t seem to get anything good going these days. As TipRanks’ Vince Condarcuri ...

Novo Nordisk's prospects look attractive despite a recent clinical setback. AstraZeneca would be performing well if not for ...

Novo Nordisk retains a strong market position in a high-growth industry, with P/E multiples poised to expand. See why NVO ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Investors in Novo-Nordisk AS (Symbol: NVO) saw new options begin trading today, for the February 2025 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NVO ...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.